Thailand’s Largest Hospital to Initiates Ivermectin Clinical Trial in COVID-19 Patients

Thailand’s Largest Hospital to Initiates Ivermectin Clinical Trial in COVID-19 Patients.

The oldest and largest hospital in Thailand, Bangkok-based Siriraj Hospital with Mahidol University, makes a move to test Ivermectin in COVID-19 patients. Founded in 1888 by King Chulalongkorn after a cholera outbreak, the hospital today has 2,221 beds. The hospital is affiliated with autonomous research institution Mahidol University

Background

Mahidol University’s Siriraj, Thailand’s largest hospital is the latest institution to embrace Ivermectin as a potential therapy for COVID-19.

The Study

Officially titled “Comparative of Ivermectin Versus Combination of Hydroxychloroquine plus Darunavir/Ritonavir for shortening the Duration of SARS-CoV-2 Detection from Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection,” the study is planned to commence in July 2020 and run through November 2021.

The open label randomized controlled Phase IV study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ritonavir for five days treatment among asymptomatic carrier of SARS-CoV-2 adult Thai population. Study outcomes under investigation include safety and duration of detectable of COVID-19 in nasopharyngeal/throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases are enrolled.

The study is led by principal investigator Rujipas Sirijatuphat, MD, who researches out of the Department of Medicine at Siriraj Hospital, Mahidol University.

About Siriraj Hospital Clinical Research Center

Siriraj Clinical Research Center maintains a fully staffed, GCP-trained professional research operation. At the research center, the team supports feasibility studies, helps with proposals and cost appraisal for bioequivalence, study of genetic formulation of drugs and Phase I studies among other activities from full Phase II through Phase IV clinical trials.

Lead Research/Investigator

Rujipas Sirijatuphat, MD

Call to ActionTrialSite News will reach out to the investigator and seek out an interview. We will update the TrialSite Network with any new information.